MedTrace Logo

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

NCT02434744 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2023-11-18

No results posted yet for this study

Summary

This study will compare the safety, tolerability and efficacy of the combination of KD026 and metformin compared to placebo and metformin on improving glycemic control in patients with type 2 diabetes mellitus.

Conditions

Interventions

DRUG

KD026

Dosed in combination

DRUG

Placebo

Dosed in combination

DRUG

Metformin

Drug prescribed by each subject's prescribing physician

Sponsors & Collaborators

  • Response Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02434744 on ClinicalTrials.gov